A Phase 2 Study of XmAb 20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer
Brief description of study
This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of XmAb20717 in patients with selected advanced gynecologic and genitourinary malignancies.
Clinical Study Identifier: s22-00496
ClinicalTrials.gov Identifier: NCT05032040
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
